Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 194

1.

Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia including Registries.

Florentin M, Kostapanos MS, Elisaf MS, Liberopoulos EN.

Curr Pharm Des. 2018 Oct 8. doi: 10.2174/1381612824666181009103440. [Epub ahead of print]

PMID:
30306861
2.

Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

Rizos CV, Elisaf MS, Skoumas I, Tziomalos K, Kotsis V, Rallidis L, Garoufi A, Athyros VG, Skalidis E, Kolovou G, Koutagiar I, Papagianni M, Antza C, Katsiki N, Ganotakis E, Liberopoulos EN.

Atherosclerosis. 2018 Oct;277:308-313. doi: 10.1016/j.atherosclerosis.2018.08.017.

PMID:
30270064
3.

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).

EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, De Marco M, Stevens CAT, Akram A, Freiberger T, Hovingh GK, Kastelein JJP, Mata P, Raal FJ, Santos RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Al-Khnifsawi M, AlKindi FA, Alnouri F, Alonso R, Al-Rasadi K, Al-Sarraf A, Ashavaid TF, Binder CJ, Bogsrud MP, Bourbon M, Bruckert E, Chlebus K, Corral P, Descamps O, Durst R, Ezhov M, Fras Z, Genest J, Groselj U, Harada-Shiba M, Kayikcioglu M, Lalic K, Lam CSP, Latkovskis G, Laufs U, Liberopoulos E, Lin J, Maher V, Majano N, Marais AD, März W, Mirrakhimov E, Miserez AR, Mitchenko O, Nawawi HM, Nordestgaard BG, Paragh G, Petrulioniene Z, Pojskic B, Postadzhiyan A, Reda A, Reiner Ž, Sadoh WE, Sahebkar A, Shehab A, Shek AB, Stoll M, Su TC, Subramaniam T, Susekov AV, Symeonides P, Tilney M, Tomlinson B, Truong TH, Tselepis AD, Tybjærg-Hansen A, Vázquez-Cárdenas A, Viigimaa M, Vohnout B, Widén E, Yamashita S, Banach M, Gaita D, Jiang L, Nilsson L, Santos LE, Schunkert H, Tokgözoğlu L, Car J, Catapano AL, Ray KK; EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators.

Atherosclerosis. 2018 Oct;277:234-255. doi: 10.1016/j.atherosclerosis.2018.08.051.

PMID:
30270054
4.

An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN.

Hormones (Athens). 2017 Jul;16(3):306-312. doi: 10.1007/BF03401525. Epub 2017 Nov 30.

PMID:
30091117
5.

Clinical pharmacology of glucagon-like peptide-1 receptor agonists.

Sfairopoulos D, Liatis S, Tigas S, Liberopoulos E.

Hormones (Athens). 2018 Sep;17(3):333-350. doi: 10.1007/s42000-018-0038-0. Epub 2018 Jun 12. Review.

PMID:
29949126
6.

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer.

Tsakiridou ED, Liberopoulos E, Giotaki Z, Tigas S.

J Clin Lipidol. 2018 May - Jun;12(3):826-829. doi: 10.1016/j.jacl.2018.03.078. Epub 2018 Mar 13.

PMID:
29650402
7.

An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN.

Hormones (Athens). 2017 Jul;16(3):200-204. doi: 10.14310/horm.2002.1749.

8.

No effect of vitamin D supplementation on cardiovascular risk factors in subjects with metabolic syndrome: a pilot randomised study.

Makariou SE, Elisaf M, Challa A, Tentolouris N, Liberopoulos EN.

Arch Med Sci Atheroscler Dis. 2017 Oct 5;2:e52-e60. doi: 10.5114/amsad.2017.70504. eCollection 2017.

9.

Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study.

Filippatos TD, Liberopoulos E, Georgoula M, Tellis CC, Tselepis AD, Elisaf M.

Arch Med Sci Atheroscler Dis. 2017 Oct 5;2:e46-e51. doi: 10.5114/amsad.2017.70502. eCollection 2017.

10.

Low high-density lipoprotein cholesterol levels improve the performance of the CHADS2 and CHA2DS2-VASc scores for the prediction of new-onset atrial fibrillation.

Barkas F, Elisaf M, Liberopoulos E.

Int J Cardiol. 2017 Nov 15;247:18. doi: 10.1016/j.ijcard.2017.07.070. No abstract available.

PMID:
28916058
11.

Uric acid and incident chronic kidney disease in dyslipidemic individuals.

Barkas F, Elisaf M, Liberopoulos E, Kalaitzidis R, Liamis G.

Curr Med Res Opin. 2018 Jul;34(7):1193-1199. doi: 10.1080/03007995.2017.1372157. Epub 2017 Sep 21.

PMID:
28836857
12.

Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.

Eleftheriadou I, Grigoropoulou P, Liberopoulos E, Liatis S, Kokkinos A, Tentolouris N.

Curr Med Chem. 2018;25(13):1549-1566. doi: 10.2174/0929867324666170530075533.

PMID:
28554326
13.

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.

Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.

Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Review.

PMID:
28521870
14.

Lipid testing in infectious diseases: possible role in diagnosis and prognosis.

Filippas-Ntekouan S, Liberopoulos E, Elisaf M.

Infection. 2017 Oct;45(5):575-588. doi: 10.1007/s15010-017-1022-3. Epub 2017 May 8. Review.

PMID:
28484991
15.

The CHADS2 and CHA2DS2-VASc scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levels.

Barkas F, Elisaf M, Korantzopoulos P, Tsiara S, Liberopoulos E.

Int J Cardiol. 2017 Aug 15;241:194-199. doi: 10.1016/j.ijcard.2017.04.062. Epub 2017 Apr 20.

PMID:
28442233
16.

Statin escape phenomenon: Fact or fiction?

Barkas F, Elisaf M, Klouras E, Dimitriou T, Tentolouris N, Liberopoulos E.

World J Exp Med. 2017 Feb 20;7(1):25-30. doi: 10.5493/wjem.v7.i1.25. eCollection 2017 Feb 20.

17.

PCSK9 in chronic kidney disease.

Pavlakou P, Liberopoulos E, Dounousi E, Elisaf M.

Int Urol Nephrol. 2017 Jun;49(6):1015-1024. doi: 10.1007/s11255-017-1505-2. Epub 2017 Jan 13. Review.

PMID:
28084558
18.

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.

EAS Familial Hypercholesterolaemia Studies Collaboration, Vallejo-Vaz AJ, Akram A, Kondapally Seshasai SR, Cole D, Watts GF, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos RD, Soran H, Freiberger T, Abifadel M, Aguilar-Salinas CA, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Ceska R, Corral P, Descamps O, Dieplinger H, Do CT, Durst R, Ezhov MV, Fras Z, Gaita D, Gaspar IM, Genest J, Harada-Shiba M, Jiang L, Kayikcioglu M, Lam CS, Latkovskis G, Laufs U, Liberopoulos E, Lin J, Lin N, Maher V, Majano N, Marais AD, März W, Mirrakhimov E, Miserez AR, Mitchenko O, Nawawi H, Nilsson L, Nordestgaard BG, Paragh G, Petrulioniene Z, Pojskic B, Reiner Ž, Sahebkar A, Santos LE, Schunkert H, Shehab A, Slimane MN, Stoll M, Su TC, Susekov A, Tilney M, Tomlinson B, Tselepis AD, Vohnout B, Widén E, Yamashita S, Catapano AL, Ray KK.

Atheroscler Suppl. 2016 Dec;22:1-32. doi: 10.1016/j.atherosclerosissup.2016.10.001. Epub 2016 Dec 7.

19.

L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.

Florentin M, Elisaf MS, Rizos CV, Nikolaou V, Bilianou E, Pitsavos C, Liberopoulos EN.

Lipids. 2017 Jan;52(1):1-9. doi: 10.1007/s11745-016-4216-z. Epub 2016 Dec 2.

PMID:
27914033
20.

Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?

Barkas F, Elisaf M, Rizos CV, Klouras E, Kostapanos MS, Liberopoulos E.

Hippokratia. 2015 Oct-Dec;19(4):332-7.

Supplemental Content

Loading ...
Support Center